Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

rPPG

Clinical trials explained: Why colour matters…

Colour can be used to emphasise mood, evoke emotions, and determine first impressions of a brand. Find how to use colour effectively in your next clinical trial campaign.

Cuttsy + Cuttsy

- PMLiVE

BioNTech acquires right to Biotheus’ bispecific antibody candidate in deal worth over $1bn

PM8002 is currently being evaluated in phase 2 studies in patients with advanced solid tumours

- PMLiVE

Bristol Myers Squibb to acquire Orum’s experimental blood cancer therapy for up to $180m

ORM-6151 has been cleared for early-stage testing in AML or myelodysplastic syndromes

EU flag

EFPIA research suggests EU proposal could further pharma innovation decline

EU incentives to invest in medicines will reduce by 55% over the next 15 years

- PMLiVE

MHRA authorises Mirati Therapeutics’ Krazati for non-small cell lung cancer

More than 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

FDA grants fast track designation to AviadoBio’s dementia gene therapy

The regulator has also given clearance for the candidate to be studied in frontotemporal dementia patients

Icons showing a clipboard

Clinical trials explained: Why branding matters…

With nearly a decade’s experience supporting clinical trials, find out why we think humanising trials through design is so important.

Cuttsy + Cuttsy

- PMLiVE

Thinking of selling your agency? Here’s what you need to know

By Jim Whitaker

- PMLiVE

bluebird bio presents positive results for inherited blood disorder gene therapies

The company’s sickle cell disease therapy was accepted for FDA priority review earlier this year

- PMLiVE

Moderna and CEPI enter pandemic preparedness partnership

The partnership aims to expand infectious disease targets for mRNA vaccine technology

- PMLiVE

Candel announces promising results for immunotherapy candidate in pancreatic cancer

Pancreatic cancer accounts for approximately 3.3% of all new cancer cases

- PMLiVE

New UK research institute launched for motor neurone disease

The research institute will bring together MND labs, clinical centres and researchers

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links